Cancer Research 2010 AACR Elections EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weinschenk, T.
Right arrow Articles by Rammensee, H.-G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weinschenk, T.
Right arrow Articles by Rammensee, H.-G.
[Cancer Research 62, 5818-5827, October 15, 2002]
© 2002 American Association for Cancer Research

Immunology

Integrated Functional Genomics Approach for the Design of Patient-individual Antitumor Vaccines1

Toni Weinschenk, Cécile Gouttefangeas, Markus Schirle, Florian Obermayr, Steffen Walter, Oliver Schoor, Raffael Kurek, Wolfgang Loeser, Karl-Horst Bichler, Dorothee Wernet, Stefan Stevanovic and Hans-Georg Rammensee2

Department of Immunology, Institute for Cell Biology [T. W., C. G., M. S., F. O., S. W., O. S., S. S., H-G. R.] and Departments of Obstetrics and Gynecology [R. K.], Urology [W. L., K-H. B.], and Transfusion Medicine [D. W.], University of Tübingen, D-72076 Tübingen, Germany

Our aim is to identify as many candidates as possible for tumor-associated T-cell epitopes in individual patients. First, we performed expression profiling of tumor and normal tissue to identify genes exclusively expressed or overexpressed in the tumor sample. Then, using mass spectrometry, we characterized up to 77 different MHC ligands from the same tumor sample. Several of the MHC ligands were derived from overexpressed gene products, one was derived from a proto-oncogene, and another was derived from a frameshift mutation. At least one was identified as an actual T-cell epitope. Thus, we could show that by combining these two analytic tools, it is possible to propose several candidates for peptide-based immunotherapy. We envision the use of this novel integrated functional genomics approach for the design of antitumor vaccines tailored to suit the needs of each patient.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
M. Condomines, D. Hose, T. Reme, G. Requirand, M. Hundemer, M. Schoenhals, H. Goldschmidt, and B. Klein
Gene Expression Profiling and Real-Time PCR Analyses Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma
J. Immunol., July 15, 2009; 183(2): 832 - 840.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Kondo, B. Maecker, M. R. Weihrauch, C. Wickenhauser, W. Zeng, L. M. Nadler, J. L. Schultze, and M. S. von Bergwelt-Baildon
Cyclin D1-Specific Cytotoxic T Lymphocytes Are Present in the Repertoire of Cancer Patients: Implications for Cancer Immunotherapy
Clin. Cancer Res., October 15, 2008; 14(20): 6574 - 6579.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Yokoyama, F. Grunebach, S. M. Schmidt, A. Heine, M. Hantschel, S. Stevanovic, H.-G. Rammensee, and P. Brossart
Matrilysin (MMP-7) Is a Novel Broadly Expressed Tumor Antigen Recognized by Antigen-Specific T Cells
Clin. Cancer Res., September 1, 2008; 14(17): 5503 - 5511.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. M. Hipp, N. Hilf, S. Walter, D. Werth, K. M. Brauer, M. P. Radsak, T. Weinschenk, H. Singh-Jasuja, and P. Brossart
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
Blood, June 15, 2008; 111(12): 5610 - 5620.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
J. J. Cragnolini and J. A. L. de Castro
Identification of Endogenously Presented Peptides from Chlamydia trachomatis with High Homology to Human Proteins and to a Natural Self-ligand of HLA-B27
Mol. Cell. Proteomics, January 1, 2008; 7(1): 170 - 180.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. N. Boss, F. Grunebach, K. Brauer, M. Hantschel, V. Mirakaj, T. Weinschenk, S. Stevanovic, H.-G. Rammensee, and P. Brossart
Identification and Characterization of T-Cell Epitopes Deduced from RGS5, a Novel Broadly Expressed Tumor Antigen
Clin. Cancer Res., June 1, 2007; 13(11): 3347 - 3355.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
A. O. Weinzierl, C. Lemmel, O. Schoor, M. Muller, T. Kruger, D. Wernet, J. Hennenlotter, A. Stenzl, K. Klingel, H.-G. Rammensee, et al.
Distorted Relation between mRNA Copy Number and Corresponding Major Histocompatibility Complex Ligand Density on the Cell Surface
Mol. Cell. Proteomics, January 1, 2007; 6(1): 102 - 113.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Sommerfeldt, F. Schutz, C. Sohn, J. Forster, V. Schirrmacher, and P. Beckhove
The Shaping of a Polyvalent and Highly Individual T-Cell Repertoire in the Bone Marrow of Breast Cancer Patients
Cancer Res., August 15, 2006; 66(16): 8258 - 8265.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Dengjel, M.-D. Nastke, C. Gouttefangeas, G. Gitsioudis, O. Schoor, F. Altenberend, M. Muller, B. Kramer, A. Missiou, M. Sauter, et al.
Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas.
Clin. Cancer Res., July 15, 2006; 12(14): 4163 - 4170.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. S. Schuetz, M. Bonin, S. E. Clare, K. Nieselt, K. Sotlar, M. Walter, T. Fehm, E. Solomayer, O. Riess, D. Wallwiener, et al.
Progression-Specific Genes Identified by Expression Profiling of Matched Ductal Carcinomas In situ and Invasive Breast Tumors, Combining Laser Capture Microdissection and Oligonucleotide Microarray Analysis.
Cancer Res., May 15, 2006; 66(10): 5278 - 5286.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
Y. Masuda, H. Itabe, M. Odaki, K. Hama, Y. Fujimoto, M. Mori, N. Sasabe, J. Aoki, H. Arai, and T. Takano
ADRP/adipophilin is degraded through the proteasome-dependent pathway during regression of lipid-storing cells
J. Lipid Res., January 1, 2006; 47(1): 87 - 98.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
S. Hofmann, M. Gluckmann, S. Kausche, A. Schmidt, C. Corvey, R. Lichtenfels, C. Huber, C. Albrecht, M. Karas, and W. Herr
Rapid and Sensitive Identification of Major Histocompatibility Complex Class I-associated Tumor Peptides by Nano-LC MALDI MS/MS
Mol. Cell. Proteomics, December 1, 2005; 4(12): 1888 - 1897.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. D. Hickman-Miller, W. Bardet, A. Gilb, A. D. Luis, K. W. Jackson, D. I. Watkins, and W. H. Hildebrand
Rhesus Macaque MHC Class I Molecules Present HLA-B-Like Peptides
J. Immunol., July 1, 2005; 175(1): 367 - 375.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Appel, A. Rupf, M. M. Weck, O. Schoor, T. H. Brummendorf, T. Weinschenk, F. Grunebach, and P. Brossart
Effects of Imatinib on Monocyte-Derived Dendritic Cells Are Mediated by Inhibition of Nuclear Factor-{kappa}B and Akt Signaling Pathways
Clin. Cancer Res., March 1, 2005; 11(5): 1928 - 1940.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Sultmann, A. v. Heydebreck, W. Huber, R. Kuner, A. Buness, M. Vogt, B. Gunawan, M. Vingron, L. Fuzesi, and A. Poustka
Gene Expression in Kidney Cancer Is Associated with Cytogenetic Abnormalities, Metastasis Formation, and Patient Survival
Clin. Cancer Res., January 15, 2005; 11(2): 646 - 655.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Dorrschuck, A. Schmidt, E. Schnurer, M. Gluckmann, C. Albrecht, C. Wolfel, V. Lennerz, A. Lifke, C. Di Natale, E. Ranieri, et al.
CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression
Blood, October 15, 2004; 104(8): 2591 - 2599.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Mocellin, E. Wang, M. Panelli, P. Pilati, and F. M. Marincola
DNA Array-Based Gene Profiling in Tumor Immunology
Clin. Cancer Res., July 15, 2004; 10(14): 4597 - 4606.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Schag, S. M. Schmidt, M. R. Muller, T. Weinschenk, S. Appel, M. M. Weck, F. Grunebach, S. Stevanovic, H.-G. Rammensee, and P. Brossart
Identification of C-Met Oncogene as a Broadly Expressed Tumor-Associated Antigen Recognized by Cytotoxic T-Lymphocytes
Clin. Cancer Res., June 1, 2004; 10(11): 3658 - 3666.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. D. Hickman, A. D. Luis, R. Buchli, S. R. Few, M. Sathiamurthy, R. S. VanGundy, C. F. Giberson, and W. H. Hildebrand
Toward a Definition of Self: Proteomic Evaluation of the Class I Peptide Repertoire
J. Immunol., March 1, 2004; 172(5): 2944 - 2952.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. R. Muller, G. Tsakou, F. Grunebach, S. M. Schmidt, and P. Brossart
Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells
Blood, March 1, 2004; 103(5): 1763 - 1769.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. M. Schmidt, K. Schag, M. R. Muller, T. Weinschenk, S. Appel, O. Schoor, M. M. Weck, F. Grunebach, L. Kanz, S. Stevanovic, et al.
Induction of Adipophilin-Specific Cytotoxic T Lymphocytes Using a Novel HLA-A2-Binding Peptide That Mediates Tumor Cell Lysis
Cancer Res., February 1, 2004; 64(3): 1164 - 1170.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Nagorsen, C. Scheibenbogen, F. M. Marincola, A. Letsch, and U. Keilholz
Natural T Cell Immunity against Cancer
Clin. Cancer Res., October 1, 2003; 9(12): 4296 - 4303.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. M. Schmidt, K. Schag, M. R. Muller, M. M. Weck, S. Appel, L. Kanz, F. Grunebach, and P. Brossart
Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells
Blood, July 15, 2003; 102(2): 571 - 576.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
A. Admon, E. Barnea, and T. Ziv
Tumor Antigens and Proteomics from the Point of View of the Major Histocompatibility Complex Peptides
Mol. Cell. Proteomics, June 1, 2003; 2(6): 388 - 398.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.